Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

BioDelivery Sciences International's Stock Jumps on FDA Approval

By George Budwell - Oct 26, 2015 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

BioDelivery Sciences' shares push higher on the news that the FDA approved the chronic pain medicine Belbuca.

What: Shares of BioDelivery Sciences International ( BDSI 3.02% )a specialty pharmaceutical company with deep interests in the areas of pain management and addiction, climbed by as much as 20.8% today on heavy volume. This sudden rise in the drugmaker's shares was caused by the announcement that the U.S. Food and Drug Administration approved Belbuca, a buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Belbuca was co-developed with Endo Pharmaceuticals, a subsidiary of Endo International ( ENDP -0.19% )

So what: The chronic pain management market is staggeringly large, with some industry experts suggesting that total sales in this area could reach $60 billion this year alone. Even so, there is a huge need for new medications that can provide relief around the clock and that are easily accessible to patients with debilitating conditions such as advanced heart disease and cancer. BioDelivery and Endo are thus hoping that Belbuca can fill this unmet medical need.

Now what: BioDelivery reportedly earned a $50 million milestone payment upon Belbuca's approval today and stands to earn royalties in the mid-to-high teen range on net sales of the drug. With Belbuca's launch scheduled for the first quarter of 2016, it could thus turn out into an important new revenue source for this tiny drugmaker next year -- especially given that the Street thinks peak sales could top $500 million a year.

Having said that, I'm personally content to wait until the drug's initial sales figures are tallied before buying shares in BioDelivery. After all, the Street frequently misses the mark when it comes to estimating new drug sales, and there's no sure fire way to tell if the market will ultimately adopt a novel drug prior to its commercial launch.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioDelivery Sciences International, Inc. Stock Quote
BioDelivery Sciences International, Inc.
$2.73 (3.02%) $0.08
Endo International plc Stock Quote
Endo International plc
$5.26 (-0.19%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.